Skip to main content

Table 1 Clinicopathological characteristics of patients who underwent R0 resection and adjuvant therapy for pancreatic cancer

From: Lymph node ratio as valuable predictor in pancreatic cancer treated with R0 resection and adjuvant treatment

Variables

N = 351

Age

63.3 ± 9.3

Sex

 - Female

148 (42.2%)

 - Male

203 (57.8%)

Body mass index, kg/m2

22.9 ± 2.7

ECOG

 - 0

289 (82.3%)

 - 1

62 (17.7%)

Charlson’s comorbidity index

4.6 ± 1.3

Tumor location

 - Head/uncinate

225 (64.1%)

 - Body

62 (17.7%)

 - Tail

52 (14.8%)

 - Overlapping

12 (3.4%)

Surgery type

 - Pancreaticoduodenectomy

232 (66.1%)

 - Distal pancreatectomy

107 (30.5%)

 - Total

7 (2.0%)

 - Subtotal

4 (1.1%)

 - Central pancreatectomy

1 (0.3%)

Histologic grade

 - Well differentiated

28 (8.0%)

 - Moderately differentiated

289 (82.3%)

 - Poorly differentiated

31 (8.8%)

 - Undifferentiated

3 (0.9%)

pT stage (AJCC 8th)

 - 1a / 1b / 1c

2 (0.6%) / 4 (1.1%) / 61 (17.4%)

 - 2

235 (67.0%)

 - 3

45 (12.8%)

 - 4

4 (1.1%)

Number of examined LNs

18.4 ± 11.7

Number of involved LNs

1.8 ± 2.6

pN stage (AJCC 8th)

 - 0

150 (42.7%)

 - 1

135 (38.5%)

 - 2

66 (18.8%)

LNR

0.1 ± 0.2

LODDS

−1.0 ± 0.5

Lymphovascular invasion

158 (45.0%)

Perineural invasion

293 (83.5%)

Preoperative laboratory findings

 - WBC, 103/μL

6.2 ± 1.9

 - Hemoglobin, g/dL

12.9 ± 1.5

 - Platelet, 103/μL

248.0 ± 79.5

 - Albumin, g/dL

4.2 ± 3.4

 - Total bilirubin, mg/dL

2.2 ± 3.5

 - AST, IU/L

43.1 ± 49.0

 - ALT, IU/L

65.7 ± 92.6

 - ALP, IU/L

157.0 ± 162.7

 - CA 19-9, U/mL

642.3 ± 1563.6

 - CEA, ng/mL

21.5 ± 300.0

  1. ECOG Eastern Cooperative Oncology Group, AJCC American Joint Committee on Cancer, LNR lymph-node ratio, LODDS log odds of positive lymph nodes, WBC white blood cell, AST aspartate Aminotransferase, ALT alanine aminotransferase, ALP alkaline phosphatase, CA 19-9 carbohydrate antigen 19-9, CEA carcinoembryonic antigen